Webinar

Mesenchymal stromal cell (MSC) therapies are entering a pivotal stage of development. As more programs move toward late-stage clinical trials and commercialization, developers must produce enough high-quality cells to meet...

Lipid nanoparticles (LNPs) are critical to the delivery of genetic medicines, but developing scalable, reproducible manufacturing processes remains complex and resource-intensive. Because LNP quality can be highly sensitive to formulation...